MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Releases Video Demonstrating Capabilities of its Proprietary Ultra Shear Technology Platform

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences industry, today released a short video that demonstrates its proprietary Ultra Shear Technology (“UST”) platform and its ability to create nanoemulsions (extremely small, nanometer-scale oil droplets that effectively dissolve in water) to provide optimized bioavailability for absorption. “We have all observed how oil and water do not normally mix or dissolve in each other, and routinely separate after mixing,” Pressure BioSciences Chief Commercial Officer Dr. Bradford A. Young said in the news release. “Even with modern, advanced mixing technologies, oils remain in relatively large drops in water, which are poorly absorbed by the body. PBI’s proprietary UST platform employs ultra-high pressure and extreme shearing forces to create very small, nano-scale emulsions (nanoemulsions) of oil droplets in water with vastly improved absorption and stability characteristics.”

To view the full press release, visit http://ibn.fm/w1H6s

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) Enters Binding Agreement to Acquire Assets of Khrysos Global

Leading omni-direct lifestyle company Youngevity International Inc. (NASDAQ: YGYI) this morning announced its entry into a binding agreement to purchase all of the assets of Khrysos Global, a Florida-based manufacturer of hemp-based CBD extraction equipment. Per the update, this acquisition is intended to establish YGYI’s newly formed, wholly owned subsidiary, Khrysos Industries Inc., as a global player in the field-to-finish hemp-CBD oil, isolate and distillate market. “I’m ecstatic about this purchase and what it signals for this moment in our company’s history,” Dave Briskie, president and CFO of YGYI, stated in the news release. “The purchase of the assets of Khrysos Global should be the catalyst that launches YGYI into the hemp-CBD space.  We expect it will serve as a cornerstone of our comprehensive strategy as it relates to the production, cultivation, and extraction of hemp, CBD oil, as well as other CBs (cannabinoids).” Closing of the transactions related to the purchase agreement is scheduled for February 15, 2019, subject to the satisfaction of various closing conditions.

To view the full press release, visit http://ibn.fm/LopnB

About Youngevity International, Inc.

Youngevity International, Inc. is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, Youngevity offers proven products from the six top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. The company was formed during the summer 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For more information, visit the company’s website at www.YGYI.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Cannabis Strategic Ventures Inc. (NUGS) Employs Niche Acquisition-Based Growth Strategy

Cannabis Strategic Ventures (OTC: NUGS), a Los Angeles-based cannabis industry incubator, recently announced its plan to uplist to the OTCQB Venture Market, a milestone that falls in line with the company’s acquisition-based growth strategy. A recent article discussing NUGS reads, “’We have many new initiatives planned in 2019, and we are managing our business operations for growth. This uplisting is designed to demonstrate to our investors and to the marketplace that Cannabis Strategic Ventures is well-prepared for the future,’ Cannabis Strategic Ventures CEO Simon Yu stated in a news release. . . . The uplisting supports the company’s broader growth strategy, which is primarily based on acquisitions of both cannabidiol brands and hard assets, such as growth facilities. A diversified portfolio will allow Cannabis Strategic Ventures to tap into multiple market niches and capitalize on the constantly growing cannabis sector.”

To view the full article, visit http://ibn.fm/l6ikj

About Cannabis Strategic Ventures Inc.

Cannabis Strategic Ventures is a Los Angeles-based firm that incubates, develops and partners with category leaders within the cannabis sector. The firm’s NUGS brand experience provides mentorship and a range of essential services to emerging and existing cannabis consumer brands. The company recently completed a name and symbol change from Cascade Energy Inc. Cannabis Strategic Ventures is publicly traded on the U.S. Over-the-Counter Market with the stock symbol NUGS. For more information, visit the company’s website at www.CannabisStrategic.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Focusing on Farm Grown, High Quality Organic Medical Cannabis

• The Green Organic Dutchman is a producer of first-rate organic cannabis
• The company recently provided a construction update on its Valleyfield and Hamilton operations
• TGOD and the Greek government have had discussions concerning the nature of proposed operational plans in the country

Established in 2012, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) focuses on the production of premium certified organic cannabis. The company’s organic process includes living soil, sustainable energy and laboratory certification and testing. Its organic processes are certified by Ecocert, one of the most astute organic certification organizations. The company’s operational emphasis is on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. Headquartered in Mississauga, Ontario, The Green Organic Dutchman is working on becoming the largest organic cannabis enterprise in the world.

TGOD is one of the lowest cost, highest quality producers in Canada and has one of the most diverse, experienced and proven management teams in Canada (http://ibn.fm/ZZX7E). The company produces farm grown, high quality organic medical cannabis in small batches. It does so employing organic craft growing principles. Its organic products are free from pesticides, herbicides and synthetic nutrients. Fundamentally, TGOD’s processes produce 100 percent non-irradiated premier organic cannabis grown in living soil.

Recently, TGOD provided a comprehensive construction update on its domestic Valleyfield, Quebec, and Hamilton, Ontario, operations. Major progress has been made toward the completion of both facilities. In January 2018, construction started on the 2,700 sq. ft. breeding facility in Valleyfield. In April 2018, the facility was completed. Moreover, in June 2018, it received a cultivation license (http://ibn.fm/jF5zC).

The engineering design improvements optimize facility throughput. This, in tandem with organic specific modifications, provides a forecast domestic productive capacity boost from 156,000 kg to 202,500 kg.

Regarding the Hamilton operations, TGOD has modified major systems from the original design. Furthermore, the company has re-engineered the whole harvesting process to enhance production uptime and facility throughput. Therefore, this has resulted in increased productive capacity from 14,000 kg to 17,500 kg. TGOD has grown and successfully harvested numerous crops in the pilot facility. It has also stored product for its forthcoming medical pilot launch.

In a news release, Brian Athaide, TGOD’s chief executive officer, said, “Not only have we addressed the important redesign requirements, we have also made significant improvements to the operating capacity and capital timing of our facilities, resulting in an additional 46,500 kgs of productive capacity.”

In addition, TGOD recently commented on the Greek Ministry of Agriculture’s press release and CNN’s (Greece) coverage (dated January 25, 2019) related to TGOD’s proposed Greece operations (http://ibn.fm/zNtfS). TGOD and the Greek government have had advanced talks regarding the nature of the proposed plans. Since early 2018, TGOD has been in communication with different Greek Ministries, including the Ministry of Rural Development and Food. The company is waiting on a license for the production of medicinal cannabis. TGOD has confirmed plans to build and commission a multi-phased facility, subject to licensing from the Greek government.

With a funded capacity of 219,000 kg, TGOD offers a compelling opportunity for perceptive investors. TGOD is constructing 1.64 million sq. ft. of facilities across Ontario, Quebec, Denmark and Jamaica. The company, with its global initiatives, is at the frontline of production of premium certified organic cannabis.

For more information, visit the company’s website at www.TGOD.ca

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Creates Unique Opportunity in Global Cannabis Industry Posted on February 11, 2019 by MissionIR

• Big corporations are investing in the cannabis industry
• Major tobacco company provides financing for LXRP
• LXRP boasts revenue streams within the nicotine industry and opportunity in other sectors
• Lexaria is a unique company doing business on its own terms

The cannabis industry is experiencing impressive growth thanks to both legal and social changes worldwide, and big corporations are stepping up to invest. In a new Audio Press Release (“APR”), CannabisNewsAudio praised Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (http://ibn.fm/sR2IL) for building a large funding deal on its own terms. The APR, ‘Outside Investment, New Technology Support Growing Cannabis Industry’, highlighted Lexaria’s ability to create subsidiaries specializing in the use of DehydraTECH.

Through the deal, Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria, has received an initial investment in the amount of $1 million – with the option for funding to increase to up to $12 million – from one of the world’s largest tobacco companies; the capital has been earmarked for research and development (http://ibn.fm/ChHLT). Lexaria will maintain its independence, while the investing company receives only minority ownership of the subsidiary. This unique arrangement allows the tobacco company to buy into LXRP without Lexaria actually selling any of its parent company.

Lexaria is strategically positioned to benefit from new revenue streams based on this deal. The company will receive royalties on any nicotine products created with DehydraTECH and be able to showcase its unique technology to other industries.

In addition to Lexaria Nicotine, LXRP has three more wholly owned subsidiaries that are working in various industries to create new deals on Lexaria’s terms.

• Lexaria CanPharm Corp. focuses on providing DehydraTECH to the global cannabis industry
• Lexaria Hemp Corp. focuses on providing DehydraTECH to the hemp-based food and supplements industry
• Lexaria Pharmaceutical Corp. focuses on licensing DehydraTECH to the pharmaceutical sectors

DehydraTECH is a drug-delivery platform patented for cannabidiol and all other non-psychoactive cannabinoids, as well as THC (tetrahydrocannabinol) and psychoactive cannabinoids. The technology is an enabling platform that works across multiple industries, thereby providing a large base of consumers with healthier forms of consumption than lighting up.

LXRP and DehydraTECH stand out among the competition. The company has a total of 10 patents issued with more than 50 patents pending worldwide. Few companies within the cannabis industry have attracted the attention of Fortune 500-type corporations, and even fewer are inking deals on their own terms. Lexaria Bioscience is one such stand-out.

For more information, visit the company’s website at www.LexariaBioscience.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Secures Supply Agreement with Ontario’s Sole Legal Retailer for Recreational Cannabis

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) this morning announced that it has secured a cannabis supply agreement with the Ontario Cannabis Retail Corporation, which operates as the Ontario Cannabis Store (“OCS”). OCS is the only legal retailer of recreational cannabis in Canada’s most-populous province. According to the update, online sales launched in October 2018 and, set to begin in April of this year, the OCS will also supply cannabis products to licensed private retail stores across the province. The first 25 retailers that are eligible to apply for cannabis licenses were announced last month. “Ontario has the largest population in Canada and is a critical component to TGOD’s national recreational rollout,” TGOD Director and CEO Brian Athaide commented in the release. “This represents the first of many provincial supply agreements planned for our premium organic product as our domestic facilities near completion and production increases throughout 2019.”

To view the full press release, visit http://ibn.fm/zIuMi

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiary Secures Key R&D Funding for Oral Nicotine Delivery Using DehydraTECH Technology

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) wholly owned subsidiary, Lexaria Nicotine LLC, recently struck a deal with a large tobacco partner, securing significant R&D financing for the company’s DehydraTECH absorption platform (http://ibn.fm/Kx7Cm). A recent article discussing the company reads, “Through the agreement, the partner also has the option to provide up to $11 million in additional research through multiple phased private financings to underwrite LXRP’s R&D. In exchange, the partner will receive certain license rights to commercialize these DehydraTECH products exclusively in the United States and non-exclusively elsewhere. The partner, the largest cigarette company in the U.S., will be obligated to pay LXRP a royalty on sales of all products that use DehydraTECH. . . . The partner will have the option to buy full ownership of LXRP’s subsidiary, but no equity in LXRP itself, per the terms of the agreement. Additionally, the partner will have the right to appoint one of the seven directors of LXRP, and, as the phased additional investments are made, it may have the right to appoint up to three directors.”

To view the full article, visit http://ibn.fm/NeyAI

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10 patents granted in the United States and Australia, and has filed over 50 patent applications worldwide across 10 patent families. Lexaria’s technology provides more rapid delivery to the bloodstream, as well as important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html